Weimin Mao - Concepedia

Author

Weimin Mao

Zhejiang Cancer Hospital

Also Known As

Mao, Weijie, W M Mao, W Mao, W. M. Mao, W. Mao, W.-M. Mao, WEI-MIN MAO, WEIMIN MAO, Wei-Min Mao, Wei-min Mao

179

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Zhejiang Cancer Hospital Sun Yat-sen University Sichuan Cancer Hospital Peking University Zhongshan Hospital

About

Weimin Mao is an author at Zhejiang Cancer Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	25	2.3K
2	Health Sciences	5	5	250
3	Public Health	3	3	236
4	Biostatistics	2	2	46
5	Natural Sciences	1	1	21

Weimin Mao

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial Hong Yang, Hui Liu, Yuping Chen, Journal of Clinical Oncology	2018	925
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Wen‐Zhao Zhong, Qun Wang, Weimin Mao, The Lancet Oncology MedicinePathologyGefitinib Versus VinorelbineEgfr-mutant NsclcAdjuvant Treatment	2017	520
Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma Hong Yang, Hui Liu, Yuping Chen, JAMA Surgery	2021	315
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial Dongsheng Yue, Shidong Xu, Qun Wang, The Lancet Respiratory Medicine MedicinePathologyErlotinib Versus VinorelbineCancer TreatmentCancer Genetics	2018	288
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial Wen‐Zhao Zhong, Qun Wang, Weimin Mao, Journal of Clinical Oncology	2020	261
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen, Journal of Clinical Oncology	2019	259
Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations Jiang Chang, Wenle Tan, Zhi‐Qiang Ling, Nature Communications	2017	251
Epidemiologic risk factors for esophageal cancer development. Weimin Mao, Weihui Zheng, Zhi‐Qiang Ling PubMed Cancer ResearchEsophagusCancer EpidemiologyEsophageal CancerCancer Risk	2011	195
Consensus Report of the 2015 Weinman International Conference on Mesothelioma Michele Carbone, Shreya Kanodia, Ann Chao, Journal of Thoracic Oncology Tumoral PathologyMedicineSurgical PathologyHistopathologyConsensus Report	2016	143
Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer Liming Sheng, Min Luo, Xiaojiang Sun, International Journal of Cancer Activated ThrombinAdvanced Lung DiseasePrognosisPathologyThrombosis	2013	111

Page 1